Arbutus Biopharma Corp Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Arbutus Biopharma Corp (ABUS) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price of $6.05 per share as of 2018-12-31, per its 10-K filed 2019-03-07.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice · last filed 2019-03-07
- 2016-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price 10.07 CAD.
- 2016-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price 11.16 CAD.
- 2016-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price 11.46 CAD.
- 2016-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price 11.01 CAD.
CAD
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2016-12-31 | 10.07 CAD 10-K · filed 2017-03-22 |
| 2016-09-30 | 11.16 CAD 10-Q · filed 2016-11-03 |
| 2016-06-30 | 11.46 CAD 10-Q · filed 2016-08-04 |
| 2016-03-31 | 11.01 CAD 10-Q · filed 2016-05-04 |
| 2015-12-31 | 21.51 CAD 10-K · filed 2016-03-09 |
USD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2018-12-31 | $6.05 10-K · filed 2019-03-07 |
| 2017-12-31 | $6.06 10-K · filed 2018-03-16 |
| 2016-12-31 | $7.50 10-K · filed 2017-03-22 |
| 2016-09-30 | $8.50 10-Q · filed 2016-11-03 |
| 2016-06-30 | $8.87 10-Q · filed 2016-08-04 |
| 2016-03-31 | $8.48 10-Q · filed 2016-05-04 |
| 2015-12-31 | $15.54 10-K · filed 2016-03-09 |
CAD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2016-12-31 | 10.07 CAD/shares 10-K · filed 2017-03-22 |
| 2016-09-30 | 11.16 CAD/shares 10-Q · filed 2016-11-03 |
| 2016-06-30 | 11.46 CAD/shares 10-Q · filed 2016-08-04 |
| 2016-03-31 | 11.01 CAD/shares 10-Q · filed 2016-05-04 |
| 2015-12-31 | 21.51 CAD/shares 10-K · filed 2016-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |